Business Wire

Arthur D. Little Joins Lunar Economic Development Organisation EURO2MOON

Share

Arthur D. Little (ADL) today announced its membership of EURO2MOON, a non-profit organisation created to promote responsible use of the Moon’s natural resources, while accelerating the cis-lunar economy across Europe. Founded by Airbus Defence and Space, Air Liquide and ispace Europe, EURO2MOON will now benefit from ADL’s extensive experience and expertise in space technology development, which stretches back to the Apollo missions of the 1960s.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005552/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Arthur D. Little today announced its membership of EURO2MOON, a non-profit organisation created to promote responsible use of the Moon’s natural resources, while accelerating the cis-lunar economy across Europe. (Photo: Business Wire)

The aim of EURO2MOON is to position Europe as taking a leading role in the development of the cis-lunar economy, creating a strong industrial ecosystem based on an ambitious “In Situ Resources Utilisation” (ISRU) vision. It will focus on the exploration of the lunar surface and the utilisation of its resources in a commercial but sustainable way. Topics to be addressed include long duration transport, life support, and energy needs for scientific and commercial applications.

ADL worked with NASA during the planning and execution of its missions to the Moon. Today, only one experiment from the Apollo 11 landing remains active and functioning – the Laser Ranging Retro-Reflector (LRRR) experiment, which ADL played a key role in developing. The LRRR’s precise measurement of Earth-Moon distances has significantly improved understanding of both terrestrial and lunar physics.

ADL has been closely involved in the commercial development of the space sector ever since, and is currently conducting a major study of future satellite applications for the European Space Agency (ESA).

Based in Luxembourg, EURO2MOON’s ultimate objective is to build a platform that supports a common industrial vision and promote it among the European industrial and institutional ecosystems, including recommendations on global roadmaps, demonstration concepts and commercial programs.

Matteo Ainardi, Leader of the Aerospace & Defense Global Center of Competence at Arthur D. Little, comments: “In the context of increased momentum around space exploration, and the development of the cis-lunar economy, the Moon will be a major focus over the coming decades. A shared European vision around both the responsible use of lunar resources and more sustainable delivery systems is essential. Space remains an area of international cooperation that should be encouraged, but this requires meaningful and effective collaboration between relevant parties. ADL is proud to be a member of EURO2MOON, which is committed to building a future united by the same ambition.”

For further information, please visit www.adlittle.com or www.adl.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Further information from:
Cate Bonthuys
Catalyst Comms
+44-7746-546773
cate@catalystcomms.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye